Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Francesco Micheletto"'
Autor:
Matheni Sathananthan, Francesca Piccinini, Chiara Dalla Man, Claudio Cobelli, Luca P. Farrugia, Francesco Micheletto, Karen B. Grothe, Michael Camilleri, Meera Shah, Adrian Vella, Robert A. Rizza, Kim L Edens
Publikováno v:
The Journal of Nutrition. 145:2046-2051
Background: Caloric restriction alone has been shown to improve insulin action and fasting glucose metabolism; however, the mechanism by which this occurs remains uncertain. Objective: We sought to quantify the effect of caloric restriction on b cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::002d7e7c179b22a15c56c4895af100fd
https://doi.org/10.3945/jn.115.210617
https://doi.org/10.3945/jn.115.210617
Autor:
Francesco Micheletto, Jörg Schirra, Chiara Dalla Man, Boris Kovatchev, Kathrin Herrmann, Elaine Chiquette, Claudio Cobelli, Orville G. Kolterman
Publikováno v:
Diabetes Technology & Therapeutics. 15:802-809
The ability to simulate in silico experiments is crucial for fast and cost-effective preliminary studies prior to clinical trials. We present an in silico approach to the design of optimal pramlintide-to-insulin (P/I) ratios, using our computer simul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85393617976d0bdf1939b1c5dbe40431
https://doi.org/10.1089/dia.2013.0054
https://doi.org/10.1089/dia.2013.0054
Autor:
Chiara Dalla Man, Matheni Sathananthan, Airani Sathananthan, Adrian Vella, Francesco Micheletto, Galina Smushkin, Claudio Cobelli, Alan R. Zinsmeister
Publikováno v:
Diabetes
The mechanisms by which common genetic variation predisposes to type 2 diabetes remain unclear. The disease-associated variants in TCF7L2 (rs7903146) and WFS1 (rs10010131) have been shown to affect response to exogenous glucagon-like peptide 1 (GLP-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1531cc686cd8ce7c7770d8b258ed39b6
https://doi.org/10.2337/db11-1732
https://doi.org/10.2337/db11-1732
Glucagon-like peptide-1 (GLP-1) is a powerful insulin secretagogue that is secreted in response to meal ingestion. The ability to quantify the effect of GLP-1 on insulin secretion could provide insights into the pathogenesis and treatment of diabetes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5d9699f1bcef17e98eadb4442ca24a5
https://europepmc.org/articles/PMC4717506/
https://europepmc.org/articles/PMC4717506/
Autor:
Chiara Dalla Man, Francesco Micheletto, Michael Camilleri, Gianna Toffolo, Paula D. Giesler, Airani Sathananthan, Claudio Cobelli, Robert A. Rizza, Adrian Vella, Jeanette Laugen, Alan R. Zinsmeister
Publikováno v:
Diabetes Care
OBJECTIVE Glucagon-like peptide (GLP)-1 receptor is encoded by GLP1R. The effect of genetic variation at this locus on the response to GLP-1 is unknown. This study assessed the effect of GLP1R polymorphisms on insulin secretion in response to hypergl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eec26ac8b02110c7c8fd969e11bda7a
http://europepmc.org/articles/PMC2928367
http://europepmc.org/articles/PMC2928367
Autor:
Dayu Lv, Boris Kovatchev, Chiara Dalla Man, Marc D. Breton, Claudio Cobelli, Francesco Micheletto
Objective: Recent studies have provided new insights into nonlinearities of insulin action in the hypoglycemic range and into glucagon kinetics as it relates to response to hypoglycemia. Based on these data, we developed a new version of the UVA/PADO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fde901c964feb8e459fc08faeef5001
http://hdl.handle.net/11577/2835503
http://hdl.handle.net/11577/2835503
Autor:
Meera Shah, Claudio Cobelli, Robert A. Rizza, Michael Camilleri, Jennie H. Law, Alan R. Zinsmeister, Chiara Dalla Man, Matheni Sathananthan, Adrian Vella, Francesco Micheletto
Publikováno v:
Diabetes
The contribution of elevated glucagon-like peptide 1 (GLP-1) to postprandial glucose metabolism after Roux-en-Y gastric bypass (RYGB) has been the subject of uncertainty. We used exendin-9,39, a competitive antagonist of GLP-1, to examine glucose met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c7b4d5356149e36d15a0fdeef7a206b
http://hdl.handle.net/11577/2835499
http://hdl.handle.net/11577/2835499
Autor:
Airani Sathananthan, Francesco Micheletto, Robert A. Rizza, Adrian Vella, Chiara Dalla Man, Claudio Cobelli
Publikováno v:
American journal of physiology. Endocrinology and metabolism. 298(6)
Glucagon-like peptide-1 (GLP-1)-based therapies for diabetes have aroused interest because of their effects on insulin secretion and glycemic control. However, a mechanistic model enabling quantitation of pancreatic response to GLP-1 has never been d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::699787437573b47a8903c09969b713ac
https://pubmed.ncbi.nlm.nih.gov/20179243
https://pubmed.ncbi.nlm.nih.gov/20179243
Autor:
Rita Basu, Gerlies Bock, Chiara Dalla Man, Paula D. Giesler, Robert A. Rizza, Adrian Vella, Carolyn F. Deacon, Jeanette Laugen, Jens J. Holst, Francesco Micheletto, Gianna Toffolo, Claudio Cobelli
Publikováno v:
Clinical Endocrinology.
Impaired fasting glucose (IFG) confers a high risk of progression to diabetes [1]. Its pathogenesis has been an area of active investigation, with defects in insulin and glucagon secretion as well as insulin action likely to play a role [2]. Several
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16338b7f3d5e92d81b3da9e0cc4414ff
https://doi.org/10.1111/j.1365-2265.2009.03764.x
https://doi.org/10.1111/j.1365-2265.2009.03764.x